“…A recent study published in Applied Health Economics and Health Policy [ 1 ] leverages results from previous decisions under the Arzneimittelmarkt-Neuordnungsgesetz (AMNOG, translated as the Pharmaceuticals Market Reorganisation Act) to ascertain the implicit willingness to pay (WTP) for pharmaceuticals from the standpoint of the German health care payer/decision maker. The study assessed WTP for drugs treating three distinct diseases in Germany after the 2011 initiation of the AMNOG process, namely, diabetes, cardiovascular disease, and psoriasis.…”